top of page

Dr. Misghina Weldegiorgis

Articles and books

Ismail S, Odland ML, Malik A, Weldegiorgis M, Newbigging K, Peden M, Woodward M, Davies J. The relationship between psychosocial circumstances and injuries in adolescents: An analysis of 87,269 individuals from 26 countries using the Global School-based Student Health Survey. PLoS Med. 2021 Sep.

Gregg EW, Sophiea MK, Weldegiorgis M: Diabetes and COVID-19: Population Impact 18 Months Into the Pandemic. Diabetes Care. 2021 Sep.

Neuen BL, Weldegiorgis M, Herrington WG, Ohkuma T, Smith M, Woodward M: Changes in GFR and Albuminuria in Routine Clinical Practice and the Risk of Kidney Disease Progression. Am J Kidney Dis. 2021 Apr

Figure 2.png

Weldegiorgis M, Woodward M: The effect of hypertension on chronic kidney disease and end-stage renal disease is greater in men than women: a systematic review and meta-analysis. BMC Nephrol. 2020 Nov.

Weldegiorgis M, Smith M, Herrington W, Bankhead C, Woodward M: Socioeconomic disadvantage and the risk of advanced chronic kidney disease: results from a cohort study with 1.4 million participants. Nephrol Dial Trans. 2020 Sep.

CKD-PC Consortium et.al.: Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 2019 Feb.

Smith M, Herrington W, Weldegiorgis M, Hobbs F, Bankhead C, Woodward M: Change in albuminuria and risk of renal and cardiovascular outcomes: natural variation should be taken into account. KI Reports. 2018 Jul.

Weldegiorgis M, de Zeeuw D, Li L, Parving HH, Hou FF, Remuzzi G, Greene T, Heerspink HJL: Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy. Am J Kidney Dis. 2018 Jan.

Weldegiorgis M, de Zeeuw D, Dwyer J, Mol PG, Heerspink HJL: Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects? Clin J Am Soc Nephrol. 2017 Sep.

Weldegiorgis M, de Zeeuw D, Heerspink HJL: Renal end points in clinical trials of kidney disease. Curr Opin Nephrol Hypertens. 2015 May.

Heerspink HJL, Weldegiorgis M, Inker LA, Gansevoort R, Parving HH, Dwyer JP, Mondal H, Coresh J, Greene T, Levey AS, de Zeeuw D: Estimated GFR decline as a surrogate end point for kidney failure. Am J Kidney Dis. 2014 Feb.

Book: Evaluation of renal end points in nephrology trials. University of Groningen. 2017 Nov; ISBN 978-94-034-0153-9

Medias

Using GFR, Albuminuria, and Their Changes in Clinical Trials and Clinical Care.

Researchers find that socioeconomic deprivation increases risk of developing chronic kidney disease in England.

Deprived are at higher risk of kidney disease.

Creatinine Linearity – Connecting the Dots Has Never Been So Complicated.

Rethinking End Points in Clinical Trials of Renoprotective Medication.

bottom of page